Literature DB >> 21292815

Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease.

Kevin S Heffernan1, Jeffrey T Kuvin, Mark J Sarnak, Ronald D Perrone, Dana C Miskulin, Darya Rudym, Priya Chandra, Richard H Karas, Vandana Menon.   

Abstract

BACKGROUND: Cardiovascular disease is the leading cause of premature mortality in autosomal dominant polycystic kidney disease (ADPKD). We examined peripheral augmentation index (AIx) as a measure of systemic vascular function and circulating markers of vascular inflammation in patients with ADPKD.
METHODS: Fifty-two ADPKD patients with hypertension and estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2), 50 ADPKD patients with hypertension and eGFR ≥ 60 mL/min/1.73 m(2), 42 normotensive ADPKD patients with eGFR ≥ 60 mL/min/1.73 m(2) and 51 normotensive healthy controls were enrolled in this study. AIx was measured from peripheral artery tone recordings using finger plethysmography. Serum levels of soluble intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule-1, P-selectin, E-selectin, soluble Fas (sFas) and Fas ligand (FasL) were measured as markers of vascular inflammation.
RESULTS: AIx was higher in all three patient groups with ADPKD compared to healthy controls (P < 0.05). AIx was similar between the normotensive ADPKD patients with eGFR ≥ 60 mL/min/1.73 m(2) and hypertensive ADPKD patients with eGFR < 60 mL/min/1.73 m(2) (P > 0.05). ICAM, P-selectin, E-selectin and sFas were higher and FasL lower in all ADPKD groups compared to controls (P < 0.05). ICAM, P-selectin and E-selectin were similar between the normotensive ADPKD patients with eGFR ≥ 60 mL/min/1.73 m(2) and hypertensive ADPKD patients with eGFR < 60 mL/min/1.73 m(2) (P > 0.05). According to multiple regression analysis, predictors of AIx in ADPKD included age, height, heart rate and mean arterial pressure (P < 0.05). Vascular inflammatory markers were not predictors of AIx in ADPKD.
CONCLUSIONS: Systemic vascular dysfunction, manifesting as an increase in AIx and vascular inflammation is evident in young normotensive ADPKD patients with preserved renal function. Vascular inflammation is not associated with elevated AIx in ADPKD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21292815      PMCID: PMC3203395          DOI: 10.1093/ndt/gfq806

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  54 in total

1.  Underestimation of vasodilator effects of nitroglycerin by upper limb blood pressure.

Authors:  K Takazawa; N Tanaka; K Takeda; F Kurosu; C Ibukiyama
Journal:  Hypertension       Date:  1995-09       Impact factor: 10.190

2.  Influence of body height on pulsatile arterial hemodynamic data.

Authors:  H Smulyan; S J Marchais; B Pannier; A P Guerin; M E Safar; G M London
Journal:  J Am Coll Cardiol       Date:  1998-04       Impact factor: 24.094

3.  Noninvasive determination of age-related changes in the human arterial pulse.

Authors:  R Kelly; C Hayward; A Avolio; M O'Rourke
Journal:  Circulation       Date:  1989-12       Impact factor: 29.690

4.  Cytokine profile in autosomal dominant polycystic kidney disease.

Authors:  M Merta; V Tesar; T Zima; M Jirsa; R Rysavá; J Zabka
Journal:  Biochem Mol Biol Int       Date:  1997-03

5.  Determinants of augmentation index in young men: the ARYA study.

Authors:  M J C A van Trijp; W J W Bos; C S P M Uiterwaal; A Oren; L E Vos; D E Grobbee; M L Bots
Journal:  Eur J Clin Invest       Date:  2004-12       Impact factor: 4.686

6.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

7.  Calcified renal stones and cyst calcifications in autosomal dominant polycystic kidney disease: clinical and CT study in 84 patients.

Authors:  E Levine; J J Grantham
Journal:  AJR Am J Roentgenol       Date:  1992-07       Impact factor: 3.959

8.  Cardiac and arterial interactions in end-stage renal disease.

Authors:  G M London; A P Guerin; S J Marchais; B Pannier; M E Safar; M Day; F Metivier
Journal:  Kidney Int       Date:  1996-08       Impact factor: 10.612

9.  Apoptosis and loss of renal tissue in polycystic kidney diseases.

Authors:  D Woo
Journal:  N Engl J Med       Date:  1995-07-06       Impact factor: 91.245

10.  Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members.

Authors:  B J Barrett; R Foley; J Morgan; D Hefferton; P Parfrey
Journal:  Kidney Int       Date:  1994-10       Impact factor: 10.612

View more
  8 in total

1.  Increased systemic inflammation is associated with cardiac and vascular dysfunction over the first 12 weeks of antiretroviral therapy among undernourished, HIV-infected adults in Southern Africa.

Authors:  Michael Bestawros; Takondwa Chidumayo; Meridith Blevins; Ashley Canipe; Jay Bala; Paul Kelly; Suzanne Filteau; Bryan E Shepherd; Douglas C Heimburger; John R Koethe
Journal:  J AIDS Clin Res       Date:  2015-03

2.  Peripheral augmentation index as a biomarker of vascular aging: an invasive hemodynamics approach.

Authors:  Kevin S Heffernan; Eshan A Patvardhan; Navin K Kapur; Richard H Karas; Jeffrey T Kuvin
Journal:  Eur J Appl Physiol       Date:  2011-12-03       Impact factor: 3.078

Review 3.  Predictors of autosomal dominant polycystic kidney disease progression.

Authors:  Robert W Schrier; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Keith Friend; Berenice Gitomer; Sandro Rossetti
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

4.  Endothelial dysfunction and oxidative stress in polycystic kidney disease.

Authors:  Jelena Klawitter; Berenice Y Reed-Gitomer; Kim McFann; Alexander Pennington; Jost Klawitter; Kaleab Z Abebe; Jacek Klepacki; Melissa A Cadnapaphornchai; Godela Brosnahan; Michel Chonchol; Uwe Christians; Robert W Schrier
Journal:  Am J Physiol Renal Physiol       Date:  2014-09-18

5.  Bioactive lipid mediators in polycystic kidney disease.

Authors:  Jelena Klawitter; Jost Klawitter; Kim McFann; Alexander T Pennington; Kaleab Z Abebe; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Berenice Gitomer; Uwe Christians; Robert W Schrier
Journal:  J Lipid Res       Date:  2013-12-16       Impact factor: 5.922

6.  Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease.

Authors:  Jelena Klawitter; Iram Zafar; Jost Klawitter; Alexander T Pennington; Jacek Klepacki; Berenice Y Gitomer; Robert W Schrier; Uwe Christians; Charles L Edelstein
Journal:  BMC Nephrol       Date:  2013-07-31       Impact factor: 2.388

7.  A Systematic Review of Reported Outcomes in ADPKD Studies.

Authors:  Sara S Jdiaa; Nedaa M Husainat; Razan Mansour; Mohamad A Kalot; Kerri McGreal; Fouad T Chebib; Ronald D Perrone; Alan Yu; Reem A Mustafa
Journal:  Kidney Int Rep       Date:  2022-07-05

8.  Neutrophil-to-lymphocyte ratio, insulin resistance, and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease.

Authors:  K Turkmen; F Tufan; E Selçuk; T Akpınar; H Oflaz; T Ecder
Journal:  Indian J Nephrol       Date:  2013-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.